. "2004-09-01T00:00:00Z"^^ . . . "article scientifique publi\u00E9 en 2004"@fr . "10.1002/ELPS.200305992" . "im September 2004 ver\u00F6ffentlichter wissenschaftlicher Artikel"@de . . . . "15349929" . "Cerebrospinal fluid amyloid\u03B2 peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloid\u03B2 peptides"@nl . . "scholarly article by Mirko Bibl et al published September 2004 in Electrophoresis"@en . . . . . "wetenschappelijk artikel"@nl . "Cerebrospinal fluid amyloid\u03B2 peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloid\u03B2 peptides"@en . "17" . "2912-2918" . . "Eckart R\u00FCther" . . . . "25" . "\u043D\u0430\u0443\u043A\u043E\u0432\u0430 \u0441\u0442\u0430\u0442\u0442\u044F, \u043E\u043F\u0443\u0431\u043B\u0456\u043A\u043E\u0432\u0430\u043D\u0430 \u0443 \u0432\u0435\u0440\u0435\u0441\u043D\u0456 2004"@uk . . "Markus Otto" . "Cerebrospinal fluid amyloid\u03B2 peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloid\u03B2 peptides"@nl . "Cerebrospinal fluid amyloid\u03B2 peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloid\u03B2 peptides"@nl . . . . . . . . . . "Cerebrospinal fluid amyloid\u03B2 peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloid\u03B2 peptides"@en . "Cerebrospinal fluid amyloid\u03B2 peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloid\u03B2 peptides"@en . . "Cerebrospinal fluid amyloid\u03B2 peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloid\u03B2 peptides"@en . . . . . . .